KATHY LAPORTE

Kathy LaPorte is an experienced founder, investor, executive and Board member. She has 35 years of experience with companies in the health technologies sector. Kathy started her venture capital career at Asset Management Company in Palo Alto, and moved over to become a General Partner of the Sprout Group where she helped build the life sciences team.

In 2005 she co-founded New Leaf Venture Partners, and in 2010 she co-founded Health Tech Capital, an angel group focused on the digital health sector. Kathy later served as Chief Business Officer and Chief Executive Officer of Nodality Inc, and on the oversight Board for the California Institute of Regenerative Medicine. She currently is an Independent Board Director of 89Bio, Bolt Biotherapeutics, D2G Oncology, Elysium Therapeutics, and Phoenix Biotech Acquisition Corp and Precipio Diagnostics.

Kathy has a B.S. degree in Biology from Yale University, summa cum laude, and an M.B.A. from the Stanford University Graduate School of Business. She served for many years on the Stanford DAPER Fund Board as well as the Stanford Business School Trust. She was named to the Forbes Midas List three times.

Kathy is passionate about helping founders, CEOs and organizations grow successfully. She is an aspiring golfer and tennis player.